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Discriminant validity of the Hospital
Anxiety and Depression Scale, Beck
Depression Inventory (II) and Beck
Anxiety Inventory to confirmed
clinical diagnosis of depression
and anxiety in patients with chronic
obstructive pulmonary disease
Tina Phan1, Owen Carter2, Claire Adams3,
Grant Waterer4, Li Ping Chung5, Maxine Hawkins6,
Cobie Rudd2, Mel Ziman1,7 and Natalie Strobel2,8
Abstract
The objective of this study was to investigate the discriminant validity of commonly used depression and anxiety
screening tools in order to determine the most suitable tool for patients with chronic obstructive pulmonary
disease (COPD). COPD patients (n ¼ 56) completed the Hospital Anxiety and Depression Scale (HADS), Beck
Depression Inventory (BDI-II) and Beck Anxiety Inventory (BAI). These scores were compared to confirmed
clinical diagnoses of depression and anxiety using the Mini Neuropsychiatric Interview. HADS depression
subscale (HADS-D) sensitivity/specificity was 78/81%; BDI-II 89/77%; HADS anxiety subscale (HADS-A) 71/
81%; and BAI 89/62%. HADS-D sensitivity/specificity was improved (100/83%) with the removal of Q4 ‘I feel
as if I am slowed down’ and adjusted cut-off (5). Removal of BDI-II Q21 ‘Loss of interest in sex’ with adjusted
cut-off 12 resulted in similar improvement (100/79%). No problematic items were identified for HADS-A or
BAI. Previously reported low sensitivity/specificity of the HADS for COPD patients was not replicated.
Furthermore, simple modifications of the HADS-D markedly improved sensitivity/specificity for depression.
BDI-II, HADS-A and BAI produced acceptable sensitivity/specificity unmodified. Pending further research
for COPD patients we recommend continued use of the HADS-A with standard cut-off (8) and removal of
Q4 of the HADS-D with lower cut-off 5.
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Introduction
Depression and anxiety are common comorbidities in
patients diagnosed with chronic obstructive pulmon-
ary disease (COPD), with benchmark prevalence esti-
mates of 40% for depression and 36% for anxiety.1
Screening COPD patients for concomitant psycholo-
gical distress is important as it has been found to
contribute to poorer health outcomes across a number
of domains, including: increased exacerbation rates,
diminished exercise performance and functional
mobility, reduced health-related quality of life,
increased number of emergency hospital visits,
increased hospitalizations, increased length of stay
as an admitted patient, increased mortality rates and
in general greater economic burden.2–8 Consequently,
European and Australasian COPD management
guidelines recommend routine screening for depres-
sion and anxiety in COPD patients using the Hospital
Anxiety and Depression Scale (HADS).9,10 Use of the
HADS with COPD patients is widespread; being
reported in at least 17 published studies.5,6,11–25 How-
ever, only two previous studies have investigated the
discriminant validity of the HADS with COPD popu-
lations and both cast doubt about its usefulness.
Cheung et al.12 confirmed clinical diagnoses of anxi-
ety disorders with 55 elderly New Zealand COPD
patients using the Mini Neuropsychiatric Interview
(MINI) and reported at the standard cut-off 8, the
HADS anxiety subscale (HADS-A) provided sensitiv-
ity/specificity of 36/90% and area under curve (AUC)
of 79%. They recommended a lower cut-off 4 that
yielded an improved sensitivity/specificity of 79/
71%. Nowak et al.26 used the German version of the
HADS depression subscale (HADS-D) to assess 259
Swiss COPD patients for depression, cross-referenced
with diagnoses of depression co-morbidity noted in
patients’ clinical records, and also reported low
discriminant validity at the standard cut-off 8 (sen-
sitivity/specificity 25/84%; AUC 66%). They recom-
mended a lower optimal cut-off score of 5 but this
still yielded fairly low sensitivity/specificity 62/63%.
These results cast doubt over the appropriateness of
using the HADS for patients with COPD. However,
these results demand replication before any firm con-
clusions can be drawn.
Potential alternatives to the HADS for COPD
patients include the Beck Depression Inventory
(BDI-II), also a popular research measure to screen
COPD patients for depression, and the counterpart for
anxiety, the Beck Anxiety Inventory (BAI). These
tests are longer than the HADS, with 21 items each,
compared to the 14 items in total for the HADS, but
are well established and popular for screening COPD
patients for studies involving cognitive behavioural
therapy.27–30 However, we are unaware of any studies
that have established the discriminant validity of
either the BDI-II or BAI in COPD patients. Therefore,
the aims of the present study were to investigate the
discriminant validity of the HADS with patients diag-
nosed with COPD, and to examine the discriminant
validity of the BDI-II and BAI as potential alterna-
tives for this population.
Method
Sample
Participants were outpatients attending community-
based COPD clinics in Perth, Western Australia. Par-
ticipants were excluded if they had a life expectancy
of less than 6 months, were currently involved in
another research study, had an illness exacerbation
resulting in hospitalization within the previous month,
were not fluent in English or were blind, deaf or diag-
nosed with dementia or Alzheimer’s disease. Ethics
approval for the study was granted by Royal Perth
Hospital, Edith Cowan University and the South Met-
ropolitan Health Service Human Research ethics
committees. We attempted to contact a list of 164
outpatients. Thirty-five individuals were uncontact-
able because they were either deceased, discharged
from the clinics, had disconnected telephones or we
were unable to contact them after five separate
attempts. Of the 129 successfully contacted, 27 did
not meet our inclusion criteria and 46 declined to
participate, citing ill-health or ‘lack of time’. The final
sample consisted of 56 patients with confirmed diag-
nosis of COPD by respiratory physicians who gave
their informed consent to participate in the study, rep-
resenting 34% of our original sampling pool, and a
consent rate of 55% of contactable and eligible parti-
cipants. The mean age of participants was 73.3 years
(SD: 8.9; range 50–91). There were more females
(58.9%) than males (41.1%) and the majority of par-
ticipants were retired (73.2%) and married or in a de
facto relationship (69.7%; Table 1).
Instruments
Participants were asked to self-complete the HADS,
BDI-II and BAI, followed immediately by a structured
clinical interview with a provisional psychologist
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conducting the MINI. The MINI (v6.0.0) is consid-
ered a ‘gold standard’ in determining incidence of
Axis I psychiatric disorders as per DSM-IV and
ICD-10 criteria.31
Statistical analyses
Aggregated and item-by-item scoreswere examined for
the HADS, BDI-II and BAI and compared to clinically
confirmed current major depression and any anxiety
disorders (panic disorder, agoraphobia and generalized
anxiety disorder) based upon MINI diagnostic criteria.
The sensitivity, specificity, Youden’s index J, positive
predictive value, negative predictive value, k coeffi-
cient and AUC values were calculated using the MINI
as the clinical standard for the presence or absence of
psychological comorbidity. Independent samples t-tests
were also used to compare themean HADS, BDI-II and
BAI scores of participants in various groups. IBMSPSS
(v22) was used for all statistical analyses.
Results
Depression
Nine of 56 patients (16.1%) met the clinical diagnosis
for major depression according to the MINI. The
mean HADS-D and BDI-II scores for these patients
are compared to others in Table 2.
Both HADS-D and BDI-II scores were signifi-
cantly different between participants with clinically
confirmed depression compared to those without.
AUC statistics for the HADS-D and BDI-II were both
close to perfect (94.8%, p < 0.001; 94.9%, p < 0.001
respectively). As can be seen in Table 3, the recom-
mended HADS-D cut-off of 8 identified 7 of 9
(77.8%) true positive cases and 38 of 47 (80.9%) true
negative cases. Youden’s index J suggested a similar
optimal cut-off of 7. The mean score of false posi-
tive cases was significantly lower (M ¼ 9.38,
SD ¼ 1.30) than true positives (M ¼ 13.86,
SD ¼ 3.29; t(8.36) ¼ 3.571, p ¼ 0.003). The rec-
ommended BDI-II cut-off 14 identified 8 of 9
(88.9%) true positive cases and 36 of 47 (76.6%) true
negative cases. Youden’s index J suggested a similar
optimal cut-off of 13. BDI-II true positives cases
had a significantly higher mean score (M ¼ 32.4,
SD ¼ 12.0) than the false negative cases (M ¼ 22.5,
SD ¼ 5.6; t(18) ¼ 2.454, p ¼ 0.025).
An examination of each item of the HADS-D using
independent samples t-tests identified the mean score
for Question 4 ‘I feel as if I am slowed down’ as
substantially higher than all other items. This was the
only item of the HADS-D for which no participant
scored zero, and the only item for which there was no
statistically significant difference in mean scores
between those with clinically diagnosed depression
(M ¼ 2.56, SD ¼ 0.73) and those without (M ¼ 2.09,
SD ¼ 0.86; t(54) ¼ 1.544, p ¼ 0.128). The sensi-
tivity and specificity of the HADS-D was therefore
recalculated when excluding this item. With Ques-
tion 4 excluded, Youden’s index J suggested an opti-
mal cut-off of 5, which detected all true positive
cases (100.0%) and 39 of 47 true negative cases
(83.0%) within our sample (Table 3). True positive
cases still had a significantly higher mean HADS-D
score (M ¼ 11.0, SD ¼ 3.22) than false positive
cases (M ¼ 6.33, SD ¼ 1.80; t(14) ¼ 3.694,
p ¼ 0.002).
Independent samples t-tests for each item of the
BDI-II also highlighted Question 21. The mean score
for Question 21 ‘Loss of interest in sex’ did not differ
significantly between those with a clinical diagnosis
of depression (M ¼ 1.30, SD ¼ 0.43) and those
without (M ¼ 1.32, SD ¼ 1.92; t(54) ¼ 1.181,
p ¼ 0.243). Therefore, the sensitivity and specificity
of the BDI-II was recalculated to exclude Question
21. Upon removal of Question 21, Youden’s index
Table 1. Participant characteristics.
Characteristic N %
Males 23 41.1
Females 33 58.9
Aboriginal or Torres Strait Islander 1 1.8
Education
Up to 10 years of school 26 46.4
11 years and above 27 48.2
Other 3 5.4
Marital status
Married/de facto 39 69.7
Not in a current relationship 17 30.3
Has a carer 41 73.2
Occupation
Employed 4 7.2
Retired 41 73.2
Other 11 19.6
GOLD stage
Mild 2 3.6
Moderate 18 32.1
Severe 25 44.6
Very severe 3 5.4
Missing 8 14.3
GOLD: Global Initiative for Chronic Obstructive Lung Disease
Classification.
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J suggested an optimal cut-off of12 that detected all
true positive cases (100.0%) and 37 of 47 true nega-
tive cases (78.7%) within our sample (Table 3).
Anxiety
Fourteen of 56 patients (25.0%) met the MINI criteria
for an anxiety disorder. This included six patients
diagnosed with panic disorder, five with agoraphobia
and three with generalized anxiety disorder. Table 2
shows the proportion and average scores of patients
identified as meeting the diagnostic criteria for any
anxiety disorder via the MINI and those meeting clini-
cally relevant anxiety symptomatology via the
HADS-A and BAI.
Independent samples t-tests suggested both HADS-
A and BAI scores were significantly different
between participants with clinically confirmed anxi-
ety disorders compared to those without. AUC statis-
tics for the HADS-A and BAI were both in the ‘fair’
range (78.4%, p < 0.001; and 78.5%, p < 0.001,
respectively). At the recommended cut-off 8 the
HADS-A identified 10 out of 14 true positive cases
(71.4%) and 34 of 42 true negative cases (81.0%).
With our sample Youden’s index J suggested an opti-
mal cut-off of 9. There were no significant differ-
ences between the mean scores of true positives (M ¼
11.20, SD ¼ 2.44) versus false positives (M ¼ 11.38,
SD ¼ 2.62; t(16) ¼ 0.146, p ¼ 0.885). With the rec-
ommended cut-off8 the BAI identified 11 of 14 true
positive cases (78.6%) and 26 of 42 true negative
cases (61.9%). For our sample, the optimal cut-off
was 12, which maintained true positives at 78.6%
but improved false negatives to 76.2% (Table 4).
No significant differences in BAI score were
found between true positive cases (M ¼ 25.10,
SD ¼ 10.23) and false positive cases either
(M¼ 18.44, SD¼ 11.01; t(16)¼1.542, p¼ 0.136).
An examination of the mean response to each ques-
tion within the HADS-A revealed no conspicuously
inflated items for COPD patients.
Examining the mean response to each question
within the BAI revealed Question 15 ‘Difficulty
breathing’ was substantially higher than other items.
However, the mean score for this question remained
statistically different between those with clinically
diagnosed anxiety (M ¼ 1.71, SD ¼ 1.07) and those
without (M ¼ 1.0, SD ¼ 1.12; t(54) ¼ 2.05,
p ¼ 0.045), suggesting discriminant validity still
existed and removal of this item was therefore not
warranted.
Discussion
The first aim of this study was to investigate the dis-
criminant validity of the HADS with patients diag-
nosed with COPD. We were unable to replicate the
findings of Cheung et al. and Nowak et al.12,26 In
contrast to Cheung et al., who found a much lower
optimal cut-off for the HADS-A of 4, our optimal
cut-off (9) was a very close approximation to the
standard recommendation of 8. The reason for the
different results is far from clear. The proportion of
our sample diagnosed with anxiety disorders (25.0%)
corresponded very closely with the sample of Cheung
et al. (25.5%) using the same diagnostic test (MINI)
and extremely similar patient profiles (Anglo-Saxon
dominant cultures, i.e., New Zealand vs. Australia).
So too, both studies had similar sample sizes (n ¼ 55
vs 56), demonstrated similar levels of discriminant
validity (AUC 79% vs 78.4%), and shared fair sensi-
tivity (79% vs 71%) and specificity (71% vs 86%) at
Table 2. Proportions and averages of depression and anxiety scores for the MINI, HADS-D, HADS-A, BDI-II and BAI.
Depression measure MINI HADS-D 8 BDI-II 14
Prevalence 16% (95% CI+ 10) 29% (95% CI+ 11.8) 34% (95% CI+ 12.4)
Average scores with depression – 12.33 (SD ¼ 4.15) 32.44 (SD ¼ 12.04)
Average scores without depression – 4.34 (SD ¼ 2.83)a 9.40 (SD ¼ 8.21)a
Anxiety measure MINI HADS-A 8 BAI 8
Prevalence 25% (95% CI 14–36%) 32% (95% CI+ 12.2) 48% (95% CI+ 13.1)
Average scores with anxiety – 9.14 (SD ¼ 4.07) 20.79 (SD ¼ 12.63)
Average scores without anxiety – 4.36 (SD ¼ 4.03)a 8.60 (SD ¼ 10.39)a
MINI: Mini Neuropsychiatric Interview; HADS-D: Hospital Anxiety and Depression Scale depression subscale; HADS-A: Hospital
Anxiety and Depression Scale anxiety subscale; BDI-II: Beck Depression Inventory; BAI: Beck Anxiety Inventory.
aDenotes statistically significant difference to participants with depression at p < 0.001.
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their optimal cut-offs. However, the COPD severity in
the population studied by Cheung et al. was not
reported, raising the question as to whether this may
have affected prevalence rates which would ulti-
mately impact on sensitivity and specificity scores.
Cheung et al. acknowledged their optimal cut-off was
‘unusually low’ and further replication of their results
was therefore warranted. The fact that we were unable
to replicate their results now casts doubt over their
suggestion of a HADS-A cut-off of 4 for COPD
patients. Further attempts to replicate the results of
Cheung et al. are needed to clarify this matter.
Contrary to Nowak et al. who suggested the
HADS-D provided poor discriminant validity for
Table 3. The sensitivity and specificity of the HADS-D, HADS-D excluding Question 4, BDI-II and BDI-II excluding
Question 21 for detecting major depression in COPD patients (%).
Cut-off points Sensitivity Specificity Youden’s index J PPV NPV
HADS-D
3 100.0 31.9 0.32 22.0 100
4 100.0 46.8 0.47 26.5 100
5 100.0 57.4 0.57 31.0 100
6 100.0 74.5 0.75 42.9 100
7a 100.0 78.7 0.79 47.4 100
8 77.8 80.9 0.59 43.8 95.0
9 77.8 85.1 0.63 50.0 95.2
10 77.8 91.5 0.69 63.6 95.5
11 55.6 95.7 0.51 71.4 91.8
HADS-D ex Qu 4
1 100.0 28.3 0.28 21.4 100
2 100.0 47.8 0.48 27.3 100
3 100.0 69.6 0.70 39.1 100
4 100.0 78.3 0.78 47.4 100
5a 100.0 82.6 0.83 52.9 100
6 88.9 87.0 0.76 57.1 97.6
7 77.8 93.5 0.71 70.0 95.7
8 55.6 95.7 0.51 71.4 91.8
9 55.6 97.8 0.54 83.3 92.0
BDI-II
9 100.0 63.8 0.64 34.6 100
10 100.0 70.2 0.70 39.1 100
11 100.0 70.2 0.70 39.1 100
12 100.0 76.6 0.77 45.0 100
13a 100.0 76.6 0.77 45.0 100
14 88.9 76.6 0.66 42.1 97.3
15 88.9 78.7 0.68 44.4 97.4
16 88.9 78.7 0.68 44.4 97.4
17 88.9 78.7 0.68 44.4 97.4
BDI-II ex Qu 21
8 100.0 61.7 0.62 33.3 100.0
9 100.0 70.2 0.70 39.1 100.0
10 100.0 74.5 0.75 42.9 100.0
11 100.0 74.5 0.75 42.9 100.0
12a 100.0 78.7 0.79 47.4 100.0
13 88.9 78.7 0.68 44.4 97.4
14 88.9 78.7 0.68 44.4 97.4
15 88.9 80.9 0.70 47.1 97.4
16 88.9 80.9 0.70 47.1 97.4
HADS-D: Hospital Anxiety and Depression Scale depression subscale; BDI-II: Beck Depression Inventory; PPV: positive predictive
value; NPV: negative predictive value.
aOptimal cut-off.
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COPD patients (AUC 66.2%), our results suggested
its discrimination was excellent (AUC 94.8%). Even
with their optimal cut-off6, Nowak et al. observed a
borderline sensitivity/specificity of 62.1/62.6% con-
trasting with our optimal cut-off 7 achieving 100.0/
78.7%, and improving even further with removal of
Question 4 and lowering the cut-off to 5 yielding
100.0/83.0%. There are many possibilities why we
were unable to replicate the results of Nowak et al.,
including vastly differing sample sizes (n ¼ 259 vs
56), differing prevalence of major depression (16.1%
vs 11.2%), use of the German versus English version
of the HADS, differing cultures and use of pre-
diagnosed depression based on medical records sub-
sequently confirmed by the patient’s physician versus
current diagnosis confirmed by a psychologist using a
structured clinical interview.
Despite the HADS being created to avoid somatic
symptom overlap with anxiety and depression in med-
ical patients, the continued use of HADS with chronic
diseases remains contentious as a variety of cut-offs
have been suggested differing from optimal cut-off
scores suggested for the general patient population,
for example, HADS-D 4 in coronary heart disease32
and HADS-D11 in end-stage renal disease.33 Given
that the discriminant validity of the HADS has only
been tested in COPD populations three times with
divergent results, the recommendation of using this
screening tool in international management guide-
lines remains contentious. More population-specific
tools, such as the Geriatric Anxiety Inventory and
COPD Anxiety Questionnaire (German: CAF), may
be preferable.34,35 However, Cheung et al. investi-
gated the Geriatric Anxiety Inventory as another alter-
native measure for use with COPD patients but found
it no more useful than the HADS, and to the best of
our knowledge the CAF has yet to be translated and
validated for use in English and we are unaware of
any others for COPD.
The second aim of our study was to examine the
discriminant validity of the BDI-II and BAI as viable
alternatives to the HADS for use with patients diag-
nosed with COPD. The BDI-II demonstrated excel-
lent discriminant validity and very similar sensitivity/
specificity to the HADS-D. Question 21 did not dis-
criminate between those with and without clinical
depression. However, its removal only marginally
improved the validity of optimal cut-offs (J ¼ 0.77
vs 0.79). Therefore, we see little value in unnecessa-
rily modifying the BDI-II for use with COPD patients.
Likewise, the BAI demonstrated similar discriminant
validity to the HADS-A. However, given the shorter
Table 4. The sensitivity and specificity of the HADS-A and BAI for detecting anxiety in COPD participants.
Cut-off points Sensitivity Specificity Youden’s index J PPV NPV
HADS-A
5 85.7 64.3 0.50 44.4 93.1
6 78.6 71.4 0.50 47.8 90.9
7 71.4 78.6 0.50 52.6 89.2
8 71.4 81.0 0.52 55.6 89.5
9a 71.4 85.7 0.57 62.5 90.0
10 64.3 85.7 0.50 60.0 87.8
11 28.6 88.1 0.17 44.4 78.7
12 14.3 90.5 0.05 33.3 76.0
13 14.3 92.9 0.07 40.0 76.5
BAI
8 78.6 61.9 0.41 40.7 89.7
9 78.6 71.4 0.50 47.8 90.9
10 78.6 76.2 0.55 52.4 91.4
11 78.6 76.2 0.55 52.4 91.4
12a 78.6 76.2 0.55 52.4 91.4
13 71.4 78.6 0.50 52.6 89.2
14 71.4 81.0 0.52 55.6 89.5
15 71.4 81.0 0.52 55.6 89.5
16 71.4 81.0 0.52 55.6 89.5
HADS-A: Hospital Anxiety and Depression Scale anxiety subscale; BAI: Beck Anxiety Inventory; PPV: positive predictive value; NPV:
negative predictive value.
aOptimal cut-off.
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length of the HADS (14 items combined) compared to
the BDI-II and BAI (42 items combined) and the free
use of the former, versus cost per test of the latter,
there may be limited advantage of using the Beck
inventories over the HADS.
The relatively modest sample size of stable COPD
patients in our study increases the probable error of
our prevalence estimates. However, they were highly
consistent with previous estimates, giving us some
reassurance that they are reasonably representative.
It is possible our study suffered selection bias;
patients suffering poorer mental health may have been
more motivated to participate, thus inflating our pre-
valence estimates. Fortunately, we achieved a consent
rate of 55% implying our data represent the majority
of our sample, thereby reducing this potential for sam-
pling error. Another potential limitation is that we did
not exclude participation in pulmonary rehabilitation
as a possible confounder, which previous evidence
suggests can be effective for reducing anxiety and
depression in COPD patients.36,37 Cheung et al. and
Nowak et al. also failed to control for this, as such
future studies should ensure that pulmonary rehabili-
tation is treated as a covariate.
Clinical implications
Since Question 4 from the HADS-D appears to be a
universal symptom of COPD patients and our data
suggests the removal of this question and lowering
the cut-off to 5 provides superior sensitivity and
specificity, we recommend this course of action when
using the HADS-D specifically with people diag-
nosed with COPD. As the HADS-A provided fair
sensitivity and specificity and no items appeared to
overlap with the symptomatology of COPD, we rec-
ommend retaining the standard cut-off point of8 for
the HADS-A until such time as future studies suggest
otherwise. Our results therefore support current
guidelines of routine use of the HADS as a screening
instrument for COPD patients, retaining the tradi-
tional HADS-A cut-off score of 8 whilst removing
Question 4 for the HADS-D and using a lower cut-off
score of 5.
Our investigation into the validity of screening
tools for use in a clinical setting further highlights the
importance of appropriate follow-up measures for
those that screen positive. However, due to the restric-
tive time frame of these measures, it is possible that
patients may feel depressed without being flagged as
suffering from clinical levels and should therefore
also be considered for follow-up. Our study found that
those clinically diagnosed with depression via the
MINI and also screened as having depression symp-
tomatology in both the HADS-D and BDI-II had sig-
nificantly higher mean scores than those that did not
screen positive. Whilst the proportion of true positive
to false positive cases was too small to be able to draw
any definitive conclusions, another avenue for future
research which has very important implications for
targeted screening and treatment may be to investi-
gate the demographic and physiological differences
(e.g. forced expired volume in one second, six-
minute walk test, number of exacerbations) in COPD
patients that may help to distinguish between these
two subgroups.
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